# A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

> **NCT00500292** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 109 (actual)

## Conditions studied

- Colorectal
- Cancer

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid

## Key facts

- **NCT ID:** NCT00500292
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-03
- **Final completion:** 2016-11
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500292, "A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00500292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*